Form 4: Bausch + Lomb Director Receives Annual Equity Grant of Over 20,000 Shares

Bausch + Lomb Corporation's Director, Hu Gaoxiang, was granted 20,338 restricted share units as part of the company's 2022 Omnibus Incentive Plan, increasing his total beneficial ownership to 61,147 common shares.

Summary

• On May 27, 2025, Hu Gaoxiang, a Director of Bausch + Lomb Corp (BLCO), acquired 20,338 common shares through an annual grant of restricted share units (RSUs).
• The RSUs were granted at a price of $0, indicating they are part of a compensation plan rather than a purchase.
• This grant was made under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• Following this transaction, Mr. Hu Gaoxiang's total beneficial ownership in Bausch + Lomb Corp stands at 61,147 common shares.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The transaction represents a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments.

Positives

• The grant of restricted share units to a non-employee director aligns the director's financial interests with those of the company's shareholders, promoting long-term value creation.
• The transaction is part of a pre-existing, disclosed incentive plan (2022 Omnibus Incentive Plan), indicating a structured approach to director compensation.

Future Outlook

The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders, converting into common shares.

Industry Context

The practice of granting restricted share units or other equity-based compensation to non-employee directors is a common and widely accepted method across various industries, including the healthcare and pharmaceutical sectors, to attract and retain qualified board members and align their interests with shareholders.

Comparison to Industry Standards

• The grant of restricted share units to non-employee directors is a standard compensation practice in publicly traded companies, including those in the healthcare and vision care sectors like Alcon (ALC), CooperCompanies (COO), and Johnson & Johnson (JNJ), which often utilize similar equity incentive plans to compensate their board members and executives.

Corporate Governance

Related Party Transactions

• The acquisition of 20,338 common shares by Director Hu Gaoxiang through an RSU grant constitutes a related party transaction, as it involves the company providing compensation to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's long-term interests with those of shareholders, potentially fostering decisions that enhance shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing, though the underlying incentive plan may apply to other personnel.

Next Steps

• The restricted share units are expected to vest immediately prior to the next annual meeting of shareholders, at which point they will settle into common shares of Bausch + Lomb Corporation.

Key Dates

Recommendation

Keywords

Bausch + Lomb, BLCO, Form 4, Insider Transaction, Restricted Share Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership